Drug Approval | October 18, 2022
Zydus receives tentative approval from USFDA for Roflumilast tablets
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Valbenazine Capsules had annual sales of US $781 million in the United States according to IQVIA data
50 lakh coloured Ayushman cards will be distributed to all the beneficiaries across Gujarat, at their doorstep, by National Health Authority empanelled agencies after doing e-KYC of beneficiaries
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
The product will be manufactured at Lupin's facility in Nagpur, India.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Subscribe To Our Newsletter & Stay Updated
